Form 10-Q · Quarterly report
The Cooper Companies 10-Q, filed Sep 9, 2026
- Filed
- CIK
- 0000711404
- Accession no.
- 0001628280-26-061160
Summary
The Cooper Companies is appealing a March 2, 2026 U.K. First-tier Tribunal decision that largely supported HMRC in a payroll tax dispute arising from its 2014 acquisition of the Sauflon Group, with an estimated loss of £0 to £71.7 million plus accrued interest. The company also disclosed that it paid $306.8 million in August 2026 to settle substantially all claims and lawsuits alleging embryo loss or reduced viability from CooperSurgical's recalled LifeGlobal embryo culture media, and that its Board approved a $1.0 billion increase to its share repurchase authorization.
Key points
- As of June 5, 2026, more than 140 lawsuits, including three uncertified putative class actions, and over 1,500 claimants had been proffered over CooperSurgical's recalled LifeGlobal embryo culture media.
- For the nine months ended July 31, 2026, resolving the claims cost $272.0 million net, consisting of a $325.8 million accrued litigation liability partially offset by $53.8 million of insurance recoveries.
- In August 2026, $306.8 million was paid to plaintiffs in settlement of substantially all of the claims, $43.8 million of it paid directly by insurance.
- The Board approved a $1.0 billion increase to the 2012 Share Repurchase Program in September 2026, bringing total authorization to $3.0 billion, with about $1.5 billion remaining; 4.9 million shares were repurchased during the quarter at an average of $69.16.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Litigation Contingencies We are or may be subject to litigation loss contingencies. We accrue for loss contingencies to the extent that we conclude that it is probable that a loss will be incurred and the amount of the loss can be reasonably estimated. If a reasonable estimate of a known or probable loss cannot be made, but a range of probable losses can be estimated, the low end of the range of losses is recognized if no amount within the range is a better estimate than any other. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.